Nursing Pharmacology Practice Questions: Anti-Seizures; Anti-Epileptic Drugs
Click on the correct answer.
Ethosuxamide (Neurontin) is mainly used to treat this seizure type:
- Generalized tonic-clonic seizures
- Absence seizures
- Infantile spasms
The mechanism of action of ethosuxamide in suppressing seizures is associated with this ion channel:
- Sodium
- Potassium
- Chloride
- Calcium
Choose which statement(s) concerning ethosuxamide pharmacokinetics is/are correct.
- About 75% of ethosuxamide is excreted in the urine as the unchanged molecule
- The major ethosuxamide metabolite is excreted as glucuronide (hydroxyethyl metabolite)
- Both
- Neither
The most frequently noted dose-related ethosuxamide side effect is gastrointestinal in nature.
- True
- False
Ethosuxamide is an effective against tonic-clonic seizures.
- True
- False
Seizure(s) which may be effectively managed by valproate:
- Tonic-clonic seizures
- Absence seizures
- Myoclonic seizures
- Partial seizures
- A & B
- B & C
- A & C
- A, B & C
- A, B, C & D
- A,B, C, D & E
Possible mechanism(s) associated with valproate antiseizure activity:
- Induction of a prolonged recovery of voltage-activated sodium channels from the inactivated state
- Slight reduction in T-type calcium currents
- Effects on GABA metabolism
- A & B
- A, B & C
Tiagabine is characterized as an adjunct therapy for treating:
- Partial seizures
- Generalized tonic-clonic seizures
- Both
- Neither
Tiagabine's mechanism of antiseizure action is likely associated with this neurotransmitter system:
- Cholinergic (nicotinic)
- Cholinergic (muscarinic)
- GABA
- Glycine
- Serotonergic
Choose (the) correct statement(s) concerning Tiagabine pharmacokinetics:
- Tiagabine exhibits 90%-100% bioavailability
- Hepatic impairment may necessitate a dosage reduction.
- Tiagabine undergoes hepatic oxidation mediated by the CYP3A cytochrome P450 isoform.
- A & C
- A, B & C
If
you wish to return to the Table of Contents in ENGLISH, press
the RETURN button above. |
Otherwise, if the text is NOT displayed in English and
you are ready to leave this page,
Press here
to return to the Table of Contents
|
|